Pharm
Carmustine
search
Carmustine
, BiCNU, Gliadel
See Also
Chemotherapy
Alkylating Agent
Indications
Astrocytoma
Brain Metastases
Brainstem
Glioma
Ependymoma
Glioblastoma
Lymphoma
Medulloblastoma
Multiple Myeloma
Mycosis Fungoides
(off-label)
Stem Cell Transplant
Mechanism
See
Alkylating Agent
Antineoplastic nitrosourea
Alkylating Agent
that cross-links DNA during all
Cell Cycle
phases
Carbamoylates
Protein
s, including DNA repair
Protein
s, resulting in further cytotoxic effects
Medications
Intravenous (BiCNU): 100 mg vial
Wafer (Gliadel): 7.7 mg
Dosing
See other references for disease specific dosing protocols
Pharmacokinetics
Highly lipophilic
Easily crosses blood brain barrier
Adverse Effects
Gene
ral
Alopecia
Bone Marrow
Suppression
Hepatotoxicity
Impaired future fertility
Nephrotoxicity
Ocular
Ocular nerve infarctions
Retina
l
Hemorrhage
Pulmonary Fibrosis
Secondary Malignancy
Adverse Effects
Infusion
Soft Tissue Injury
if extravasates
Run infusion over 2 hours to prevent extravasation
Adverse Effects
Wafer
Seizure
s
Brain edema (including risk of
Cerebral Herniation
)
CNS Infection
Safety
Avoid in
Lactation
Avoid in pregnancy (contraindicated in all trimesters)
Teratogen
ic and adverse outcomes
Use reliable
Contraception
Monitoring
Complete Blood Count
Liver Function Test
s
Renal Function
tests
Pulmonary Function Test
s
Drug Interactions
Drugs that increase Carmustine effects (esp. myelosuppression)
Cimetidine
Carmustine decreases other drug levels
Digoxin
Phenytoin
Resources
Carmustine IV (BiCNU, DailyMed)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0bdd91e1-fd94-4ce8-9c99-1b0fa6fe8ae4
Carmustine Wafer (Gliadel, DailyMed)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38962a55-a514-4c48-bea5-f99a8da4beec
Type your search phrase here